Contents

List of plates and figures xiv
List of tables xvi
About the editors xvii
List of contributors xix
From the series editor xxi
Preface xxiii

Section I

Introduction 1

Introduction 3
SHANE S. BUSH AND THOMAS A. MARTIN

Settings 3
Referral questions 3
Diagnosis 4
Treatment 4
Consumer education/prevention 5
Conclusion 5
References 5

Section II

Assessment 9

1 The clinical interview 11

JACOBUS DONDERS

Understanding the referral 11
Making the first contact 12
Beginning the interview 13
History of the presenting problem 14
Contents

Other personal history  15
Wrapping up  17
Conclusion  18
References  18

2 Selection and use of screening measures in geriatric neuropsychology  21
JEAN LENGENFELDER AND JOHN DELUCA

Screening for mental status/cognitive functioning  23
Screening for depression and other psychiatric symptoms  31
Screening for behavioral or functional impairment  32
Conclusions  34
References  34

3 Neuropsychological batteries for older adults  41
JOHN L. WOODARD AND BRADLEY N. AXELROD

What is neuropsychological assessment of the older patient?  42
Complicating variables with older adults  42
Special needs of older adults during neuropsychological assessment  45
Neuropsychological batteries for older adults  46
Fixed battery approaches  49
Flexible battery approaches  56
Functional capacity  64
Symptom validity testing with older adults  71
Summary  72
References  73

4 Applications of technology to assessment and intervention with older adults  85
PHILIP SCHATZ

Applications of Internet use with older adults  85
Applications of technology to assessment of older adults  86
Technological adaptations in neuropsychological assessment  89
Summary  92
References  92

5 Test accommodations in geriatric neuropsychology  97
BRUCE CAPLAN AND JUDITH A. SHECHTER

Pertinent professional standards and guidelines  98
Factors that may warrant nonstandard modification in the assessment of older adults  102
Contents ix

Research on specific modifications 104
Conclusion 109
Notes 110
References 110

6 Cultural considerations in the neuropsychological assessment of older adults 115

DESIREE A. BYRD AND JENNIFER J. MANLY

Definition of culture 116
Culture and geriatric assessment 116
Dementia 125
Sources of cultural effects on neuropsychological test performance 125
Conclusions 130
References 131

7 Structural and functional neuroimaging findings in normal and pathological aging 141

JAMES T. BECKER, HOWARD AIZENSTEIN, AND MERYL A. BUTTERS

Structural neuroimaging 141
Functional neuroimaging 148
Summary and conclusions 155
Acknowledgements 155
Note 155
References 155

Section III

Neuropsychological disorders 165

8 Neuropsychology of Alzheimer’s disease and other dementias 167

RONALD F. ZEC AND NICOLE R. BURKETT

Chapter overview 167
Epidemiology 168
Neuropathology of Alzheimer’s disease 168
Neuropathologic criteria for the diagnosis of AD 171
The use of neuropsychological assessment in the diagnosis of Alzheimer’s disease 172
Early detection of Alzheimer dementia 174
Brief mental status tests and neuropsychological batteries for evaluation of dementia 175
Attention 177
9 Cerebrovascular disorders: Neurocognitive and neurobehavioral features

STEPHEN N. MACCIIOCCHI, AMY L. ALDERSON, AND SARA L. SCHARA

Epidemiology and risk 219
Pathophysiology 221
Neurocognitive-neurobehavioral networks and stroke 222
Neurovascular syndromes: Neurobehavioral and neurocognitive features 225
Functional outcome 236
Summary and conclusions 239
References 239

10 Neuropsychology of Parkinson’s disease and its dementias

ALEXANDER I. TRÖSTER AND STEVEN PAUL WOODS

Historical perspectives 243
Epidemiology and genetics 244
Neuropathology and pathophysiology 246
Neurobehavioral features of Parkinson’s disease 250
purposes of clinical neuropsychological assessment 263
Process-oriented assessment of the patient with Parkinson’s disease 264
Comments on differentiating Lewy body, Parkinson’s, and Alzheimer’s dementias 273
Impact of pharmacological and surgical treatments on cognition 273
Acknowledgement 278
References 278
11 Traumatic brain injury and the older adult 301
THOMAS A. MARTIN AND BRICK JOHNSTONE

Neuropathology of traumatic brain injury 302
Neuropsychological sequelae of traumatic brain injury in the older adult 305
Neuropsychological assessment of older adults with traumatic brain injury 308
Interpretation of data for older adults with traumatic brain injury 312
Treatment considerations for older adults with traumatic brain injury 314
Conclusion 317
References 317

Section IV
Clinical considerations 325

12 Co-occurring psychiatric and neurological impairments in older adults 327
MARY R. HIBBARD, SABRINA BREED, TERESA ASHMAN, AND JULIE WILLIAMS

Unique diagnostic issues in older adults 327
Depression in older adults 328
Anxiety disorders in older adults 336
Psychotic disorders in older adults 340
Psychiatric interventions with older adults 341
Psychotherapeutic interventions with older adults 342
Conclusions 349
Acknowledgements 350
References 350

13 Sleep disorders and geriatric neuropsychology 363
MANFRED F. GREIFFENSTEIN

Basic sleep terminology 363
Measurement issues in sleep medicine 365
Sleep and aging 369
Neuropsychological studies 375
Concluding comments 378
References 378
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td><strong>Geriatric pain and neuropsychological assessment</strong>&lt;br&gt;FELICIA HILL-BRIGGS, JENNIFER JACOBSON KIRK, AND STEPHEN T. WEGENER</td>
<td>385</td>
</tr>
<tr>
<td></td>
<td><em>Pain classification, prevalence, and underdiagnosis</em> 385&lt;br&gt;<em>Neurological mechanisms of pain in aging and dementia</em> 386&lt;br&gt;<em>Pain assessment in older adults</em> 388&lt;br&gt;<em>Pain assessment in populations with severe cognitive impairment</em> 390&lt;br&gt;<em>Neuropsychological functioning in chronic pain patients</em> 390&lt;br&gt;<em>Clinical recommendations</em> 395&lt;br&gt;<em>References</em> 396</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td><strong>Geriatric psychopharmacology</strong>&lt;br&gt;EFRAIN A. GONZALEZ, MARGARET M. MUSTELIER, AND JOSE A. REY</td>
<td>401</td>
</tr>
<tr>
<td></td>
<td><em>Pharmacodynamics and pharmacokinetics</em> 401&lt;br&gt;<em>Pharmacological treatment of common geriatric disorders</em> 402&lt;br&gt;<em>Neurocognitive effects of select medications commonly prescribed to older adults</em> 419&lt;br&gt;<em>Neurocognitive effects of dietary supplements</em> 420&lt;br&gt;<em>Polypharmacy</em> 422&lt;br&gt;<em>Conclusions</em> 423&lt;br&gt;<em>References</em> 423</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td><strong>Substance abuse in older adults</strong>&lt;br&gt;DOUG JOHNSON-GREENE AND ANJELI B. INSCORE</td>
<td>429</td>
</tr>
<tr>
<td></td>
<td><em>Alcohol abuse</em> 429&lt;br&gt;<em>Drug abuse</em> 436&lt;br&gt;<em>Conclusions</em> 443&lt;br&gt;<em>Acknowledgements</em> 443&lt;br&gt;<em>References</em> 443</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td><strong>Neuropsychologists as family service providers after the onset of neurological disorders in older adults</strong>&lt;br&gt;LAURA A. TAYLOR, LEE A. LIVINGSTON, JEFFREY S. KREUTZER, AND DEBORAH D. WEST</td>
<td>453</td>
</tr>
<tr>
<td></td>
<td><em>Family issues, reactions, and needs</em> 454&lt;br&gt;<em>The role of neuropsychologists in helping families</em> 457&lt;br&gt;<em>Neuropsychological assessment</em> 459&lt;br&gt;<em>Treatment options</em> 466&lt;br&gt;<em>Greatest challenges for geriatric patients and their families</em> 476</td>
<td></td>
</tr>
</tbody>
</table>
18 Decision-making capacity in the impaired older adult

PAUL J. MOBERG AND MAUREEN GIBNEY

Measurement concerns 493
Decision-making capacity evaluation in clinical contexts 495
Decision-making capacity and guardianship 496
Clinical rating scales of capacity 497
Neuropsychological assessment of capacity 500
Summary and conclusions 502
Acknowledgement 503
References 503

19 Ethical issues in geriatric neuropsychology

SHANE S. BUSH AND THOMAS A. MARTIN

Ethical decision making 508
Salient ethical issues: An overview 508
Application of general ethical principles to geriatric neuropsychology 509
Select topics of ethical concern in geriatric neuropsychology 511
Neuropsychological treatment 529
Conclusions 532
References 532

Appendix: Resources for the practice of geriatric neuropsychology 537

Index 543
List of plates and figures

Color plates (Chapter 7)

7.1 The results of the VBM analysis comparing probable AD patients with healthy, elderly controls. The voxels that had significantly decreased volume in the patients compared to the controls is rendered onto the surface of an individual, control subject’s brain

7.2 Coronal image from SPM showing area of decreased gray matter volume in AD patients with psychosis (compared to healthy control subjects)

7.4 Results of VBM analysis comparing gray matter volumes in MCI-A (left column) and MCI-MCD (right column) to normal control subjects. The top row shows the regions of cortical atrophy projected onto an average brain image. The bottom row shows the regional atrophy projected onto a coronal section through an average MCI patient brain

7.5 Three-dimensional mesh images of the hippocampus showing areas of atrophy in AD patients

7.6 Three-dimensional mesh images of the hippocampus showing areas of atrophy in MCI patients. The left-hand image shows the areas of atrophy in the amnesic MCI cases, while the right-hand image shows the atrophy in the MCI-MCD cases. Although the MCI-A cases had significantly smaller hippocampi than did the controls, the MCI-MCD cases did not

7.7 The relationship between hippocampal atrophy and depression. The figure on the left shows the correlation (overlaid onto a coronal section through the hippocampus) between brain volume and years since first depressive episode. The right-hand figure shows the same relationship, but plotted as a function of time

7.8 Multislice CASL perfusion maps in elderly volunteer at 1.5 T. Alternating label and control images were acquired using a 3.7 s RF irradiation period, 0.7 s transit delay, and a 1 s multislice acquisition using echo planar imaging (EPI: 64 × 64, 20 cm field of view, 21 ms
echo time, 90° flip angle, 5 mm thick, 0 spacing) (courtesy of H. Michael Gach, University of Pittsburgh)

7.10 Regional CBF in the posterior insulate cortex among AD patients with a better response to cholinesterase inhibition

7.11 FDG scans of brain metabolism in AD and DLB. The left-hand image shows an AD patient with decreased glucose metabolic activity in the right parietal cortex, and preservation of occipital metabolism. The right-hand image shows the metabolism of a DLB patient with more severe (and bilateral) metabolic reductions, most prominent in the parietal and the occipital cortices (courtesy of N. Bohnen, University of Pittsburgh)

7.12 Example of visualization of beta-amyloid using the Pittsburgh Compound-B, and brain metabolism as shown by FDG (courtesy of W. Klunk, University of Pittsburgh)

7.13 Co-registered PET and MR images of a healthy 74-year-old man, showing the distribution of 5-HT1A receptors, including midbrain region of the raphe and hippocampus (top row, middle image). Lack of binding in the cerebellum, where there are negligible 5-HT1A receptors, is also demonstrated (top row, left image) (courtesy of C. C. Meltzer, University of Pittsburgh)

Figures

7.3 The relationship between middle temporal gyrus volume and performance on the naming subtest of the ADAS. The volumes were calculated using the method of Convit et al., 1995

7.9 Alterations in the HRF in normal aging. The time series for visual (left side) and motor (right side) ROIs are shown here. Solid line represents mean young (n = 9) percentage signal change from baseline, dotted line is elderly (n = 9) percentage signal change. Error bars represent +/- 1 SEM

7.14 Scatter plots depict a positive correlation between the patient serotonin binding potential and pretreatment Hamilton Depression Rating score (left-hand graph), and the correlation with time to remission (right-hand graph) (courtesy of C. C. Meltzer, University of Pittsburgh)

10.1 Frontostriatal circuit dysfunction in Parkinson’s disease. Solid arrows: inhibitory influence; open arrows: excitatory influence; narrow arrows: underactive relative to normal; medium arrows: relatively unaffected in PD; broad arrows: overactive relative to normal

17.1 Excerpt from the informant version of the Judgment and Safety Screening Inventory. Reproduced with permission of the authors (Kreutzer et al., 2001)
### List of tables

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Variables to explore in a clinical neuropsychological interview</td>
<td>16</td>
</tr>
<tr>
<td>2.1</td>
<td>Administration time of cognitive screening measures</td>
<td>23</td>
</tr>
<tr>
<td>3.1</td>
<td>A proposed flexible battery to assess elderly patients</td>
<td>70</td>
</tr>
<tr>
<td>7.1</td>
<td>CBF changes in dementia</td>
<td>149</td>
</tr>
<tr>
<td>9.1</td>
<td>Neurobehavioral and neurocognitive features of stroke</td>
<td>226</td>
</tr>
<tr>
<td>10.1</td>
<td>Braak staging of neuropathology in Parkinson’s disease</td>
<td>247</td>
</tr>
<tr>
<td>10.2</td>
<td>Probabilistic criteria for the diagnosis of Parkinson’s disease</td>
<td>251</td>
</tr>
<tr>
<td>10.3</td>
<td>Self-report and rating scales with empirically modified cutoff scores</td>
<td>272</td>
</tr>
<tr>
<td></td>
<td>to detect depression in Parkinson’s disease</td>
<td></td>
</tr>
<tr>
<td>10.4</td>
<td>Possible neurobehavioral effects of medications commonly used</td>
<td>274-275</td>
</tr>
<tr>
<td></td>
<td>in the treatment of Parkinson’s disease</td>
<td></td>
</tr>
<tr>
<td>10.5</td>
<td>Possible neurobehavioral effects of modern surgical interventions</td>
<td>276</td>
</tr>
<tr>
<td></td>
<td>for Parkinson’s disease</td>
<td></td>
</tr>
<tr>
<td>13.1</td>
<td>Sample sleep report</td>
<td>364-365</td>
</tr>
<tr>
<td>14.1</td>
<td>Observation scales for pain assessment in persons with severe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cognitive impairment</td>
<td>391</td>
</tr>
<tr>
<td>15.1</td>
<td>Medications used to treat Alzheimer’s disease</td>
<td>404</td>
</tr>
<tr>
<td>15.2</td>
<td>Typical and atypical antipsychotic medications</td>
<td>412</td>
</tr>
<tr>
<td>15.3</td>
<td>Selected medications with anticholinergic properties</td>
<td>418-419</td>
</tr>
<tr>
<td>16.1</td>
<td>Possible characteristics of problem drinking in elderly patients</td>
<td>431</td>
</tr>
<tr>
<td>16.2</td>
<td>Screening instruments for assessment of problem drinking in the elderly</td>
<td>431</td>
</tr>
<tr>
<td>17.1</td>
<td>Common referral questions relating to evaluation and</td>
<td>460</td>
</tr>
<tr>
<td></td>
<td>treatment of family members of geriatric patients</td>
<td></td>
</tr>
<tr>
<td>17.2</td>
<td>Common questions posed by family members of geriatric patients</td>
<td>461</td>
</tr>
<tr>
<td>17.3</td>
<td>Questions used to assess family change and family reactions</td>
<td>464</td>
</tr>
<tr>
<td>17.4</td>
<td>Sample recommendations for optimizing functioning of the</td>
<td>467-470</td>
</tr>
<tr>
<td></td>
<td>geriatric patient</td>
<td></td>
</tr>
<tr>
<td>17.5</td>
<td>Sample recommendations for optimizing family members’</td>
<td>470-471</td>
</tr>
<tr>
<td></td>
<td>functioning</td>
<td></td>
</tr>
<tr>
<td>18.1</td>
<td>Terms used to define the targets of decisional capacity assessments</td>
<td>502</td>
</tr>
</tbody>
</table>